Abstract:OBJECTIVE:With the widespread application of peripherally inserted central catheters (PICC) in neonatal intensive care unit (NICU), the incidence of invasive fungal infections increased significantly than ever. The present study aimed to explore the clinical significance of oral fluconazole in premature infants with gestational age ≤ 32 weeks and/or birth weight ≤ 1500 grams who had catheter insertions.METHOD:This study enrolled 118 infants admitted between January 2006 and December 2007 who did not receive fluconazole prophylaxis (control group) and 106 infants admitted between January 2008 and June 2009 who received oral fluconazole prophylaxis (prophylaxis group). Statistical analyses were performed by using SPSS 11.5 software. The clinical characteristics and the risk factors for invasive fungal infection between the two groups were compared. Liver functions (alanine transaminase, ALT and direct bilirubin) were monitored to evaluate the safety of fluconazole prophylaxis.RESULT:Except for the proportion of infants born via vaginal delivery in the control group (56/118, 47.5%) was significantly lower than that in prophylaxis group (69/106, 65.1%, P = 0.007), there were no significant significant differences in the demographics and other baseline clinical characteristics between the two groups. There were no significant differences in the risk factors for invasive fungal infection between the two groups either. Nine infants developed invasive fungal infection in control group (7.6%), while no invasive fungal infection was found in prophylaxis group (0%, P = 0.01). Compared to infants in control group, those in prophylaxis group showed no significant changes in alanine transaminase ALT and direct bilirubin levels at 2 weeks and 4 weeks after fluconazole prophylaxis: the incidences of abnormal ALT and direct bilirubin levels were 8.5% (10/118) and 6.8% (8/118) in control group compared to 11.3% (12/106) and 8.5% (9/106) in prophylaxis group after 2 weeks (P = 0.47 and 0.63); the incidences of abnormal ALT and direct bilirubin levels were 3.4% (4/118) and 3.4% (4/118) in control group compared to 5.7% (6/106) and 8.5% (9/106) in prophylaxis group after 4 weeks (P = 0.62 and 0.15).CONCLUSION:For infants with PICC insertions and gestational ages at birth ≤ 32 weeks and/or low birth weight ≤ 1500 grams, oral fluconazole is effective to prevent invasive fungal infection. Oral fluconazole in premature infants neither affected the liver function, nor increased the incidence of cholestasis.

Population Pharmacokinetics of Fluconazole Administered Orally in Pregnant Women

The Safety of Oral Fluconazole During the First Trimester of Pregnancy: a Systematic Review and Meta‐analysis

Embryo Tissue and Plasma Concentration of Fluconazole in Pregnant Women Assayed by HPLC

Clinical Significance of Oral Fluconazole Prophylaxis Against Invasive Fungal Infection in Preterm Neonates with Peripherally Inserted Central Catheters

Population pharmacokinetics of fluconazole for prevention or treatment of invasive candidiasis in Chinese young infants

Safety of Efavirenz in First-trimester of Pregnancy

Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial

[Meta-Analysis of the Efficacy and Safety of Fluconazole in Prophylaxis of Fungal Infection in Very Low Birth Weight Infants].

Influence of Prophylactic Application of Fluconazole on Antifungal Susceptibility to Strains of Candida Isolated from the Patients with High Risk of Deep Fungal Infections

Clinical Characteristic and Antifungal Drug Sensitivity of Candida Parapsilosis Infections in Blood of Neonates

Analysis of the Susceptibility to COVID-19 in Pregnancy and Recommendations on Potential Drug Screening.

Study on clinical pharmacology of Metronidazole in pregnant and breast- feeding women

Concentrations of Fluoxetine Enantiomers Decline During Pregnancy and Increase After Birth

Role of Measuring the Concentration of Circulating Non-host fetal DNA of Pregnant Women Plasma in Premature Delivery

Anti‐Infective Dosing in Special Populations: Pregnancy

Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for Candida infections

Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations

Physiologically based pharmacokinetic modeling to predict maternal pharmacokinetics and fetal carbamazepine exposure during pregnancy

Systematic Quantitative Analysis of Fetal Dexamethasone Exposure and Fetal Lung Maturation in Pregnant Animals: Model Informed Dexamethasone Precision Dose Study

Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model

The relationship between early pregnancy serum HCY level and serum folic acid level with unexplained spontaneous abortion